Jobs with Catabasis Pharmaceuticals, Inc. We use cookies to give you a better BioSpace experience. By continuing to use our site, you are agreeing to the use of cookies as set in our  Privacy Policy . Skip to main content 161 First Street Suite 1A Cambridge Massachusetts 02142 United States Tel: 617-349-1971 Fax: 617-273-2637 Website:   http://www.catabasispharma.com/ Email:   info@catabasispharma.com 11/7/2019 Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020  10/24/2019 Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019. 10/18/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the Child Neurology Society 48th Annual Meeting to be held October 23-26 in Charlotte, North Carolina. 10/5/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent 9/30/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD).  9/27/2019 Catabasis Pharmaceuticals, Inc. announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy will be presented at the 24th International Congress of the World Muscle Society, being held October 1-5, 2019, at the Tivoli Garden Concert Hall in Copenhagen, Denmark. 9/26/2019 Edasalonexent Inhibits NF-kB, a Potential Driver of Disease Progression in Dysferlinopathy 9/25/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Andrew A. Komjathy as Chief Commercial Officer. 8/9/2019 8/8/2019 Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2019 and reviewed recent business progress. 8/7/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Hugh M. Cole to its Board of Directors. 8/6/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 7/25/2019 The Company will host a conference call at 8:30am ET 6/27/2019 Patient Identification Nearing Completion for Global Phase 3 PolarisDMD Trial for Edasalonexent in Duchenne Muscular Dystrophy 6/21/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD) 6/18/2019 Catabasis Pharmaceuticals, Inc. announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy, at two upcoming meetings: the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and the Parent Project Muscular Dystrophy 25th Annual Conference. 5/14/2019 Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Enrolling Boys Globally  5/2/2019 Catabasis Pharmaceuticals, Inc. announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy from the MoveDMD trial open-label extension at the American Academy of Neurology 71st Annual Meeting to be held May 4 to May 10, 2019 in Philadelphia, PA. 4/30/2019 Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report first quarter 2019 financial results before the Nasdaq Global Market open on Tuesday, May 14, 2019. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss first quarter financial results. 4/1/2019 Catabasis Pharmaceuticals, Inc. announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Phase 3 PolarisDMD trial, at two major medical meetings in April: the 12th UK Neuromuscular Translational Research Conference and the 2019 Muscular Dystrophy Association Clinical and Scientific Conference. Back to top  1985 - 2019 BioSpace.com. All rights reserved. Powered by Madgex Job Board Software 